StockData
Veru Inc. logo

Veru Inc. (VERU) stock

VERUNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026Score 6/30
$2.08−0.01 (-0.48%)

Close on Nov 16, 2026Market cap $35.46MP/E –Yield –

Veru ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Veru's ebitda for the twelve months ending Jun 30, 2026 was -$19.08M. For fiscal 2025 it was -$24.60M. The highest annual figure on record is $11.40M in fiscal 2012.

Annual ebitda

PeriodPeriod endValueChange
FY2025Sep 30, 2025-$24.60M–
FY2024Sep 30, 2024-$35.90M–
FY2023Sep 30, 2023-$93.51M–
FY2018Sep 30, 2018-$20.70M–
FY2017Sep 30, 2017-$8.16M-337.1%
FY2016Sep 30, 2016$3.44M-51.6%
FY2015Sep 30, 2015$7.11M+57.6%
FY2014Sep 30, 2014$4.51M-56.4%
FY2013Sep 30, 2013$10.35M-9.3%
FY2012Sep 30, 2012$11.40M+203.2%
FY2011Sep 30, 2011$3.76M-21.9%
FY2010Sep 30, 2010$4.82M-3.4%
FY2009Sep 30, 2009$4.99M–

Quarterly ebitda

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026-$7.69M–
Q2 FY2026CQ1 2026Mar 31, 2026-$7.19M–
Q1 FY2026CQ4 2025Dec 31, 2025-$5.40M–
Q4 FY2025CQ3 2025Sep 30, 2025$1.20M–
Q3 FY2025CQ2 2025Jun 30, 2025-$7.52M–
Q2 FY2025CQ1 2025Mar 31, 2025-$8.09M–
Q1 FY2025CQ4 2024Dec 31, 2024-$10.18M–
Q4 FY2024CQ3 2024Sep 30, 2024-$9.28M–
Q3 FY2024CQ2 2024Jun 30, 2024-$10.48M–
Q2 FY2024CQ1 2024Mar 31, 2024-$8.82M–
Q1 FY2024CQ4 2023Dec 31, 2023-$7.32M–
Q4 FY2023CQ3 2023Sep 30, 2023-$8.11M–
Q1 FY2019CQ4 2018Dec 31, 2018-$969.17K–
Q4 FY2018CQ3 2018Sep 30, 2018-$3.73M–
Q3 FY2018CQ2 2018Jun 30, 2018-$4.92M–
Q2 FY2018CQ1 2018Mar 31, 2018-$4.65M–
Q1 FY2018CQ4 2017Dec 31, 2017-$7.39M–
Q4 FY2017CQ3 2017Sep 30, 2017-$2.71M–
Q3 FY2017CQ2 2017Jun 30, 2017-$1.18M–
Q2 FY2017CQ1 2017Mar 31, 2017-$2.49M–
Q1 FY2017CQ4 2016Dec 31, 2016-$1.79M–
Q4 FY2016CQ3 2016Sep 30, 2016-$197.75K–

More Veru figures

See a number that looks wrong?